asco 2018: dr. westin sheds light on parp inhibitor abstracts in ovarian cancer
Published 6 years ago • 398 plays • Length 5:32Download video MP4
Download video MP3
Similar videos
-
1:07
dr. westin on emerging parp inhibitors in ovarian cancer
-
1:48
dr. westin on advances made with parp inhibitors in ovarian cancer
-
0:57
dr. westin on parp resistance in ovarian cancer
-
1:06
gynecologic oncology at asco 2018: olaparib and vistusertib, westin
-
6:35
asco 2018: dr. birrer on practice-changing ovarian cancer studies
-
7:53
asco 2018: dr. coleman shares insight on ongoing research in ovarian cancer
-
5:34
differences among parp inhibitors in ovarian cancer
-
1:40
dr. hardesty on bevacizumab/parp inhibitor combination in ovarian cancer
-
3:44
the future role of parp inhibition in ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
2:35
dr. monk on choosing between parp inhibitors in ovarian cancer
-
6:20
parp inhibitors in recurrent ovarian cancer
-
1:38
dr. chase on niraparib as frontline maintenance therapy in ovarian cancer
-
1:26
dr. penson on biomarkers of response to parp inhibitors in ovarian cancer
-
6:25
combinations with parp inhibitors for ovarian cancer
-
4:17
maintenance therapy in ovarian cancer: parp inhibitors
-
9:39
parp inhibitor selection in ovarian cancer
-
1:09
dr. zakashansky on repeat exposure to parp inhibitors in patients with ovarian cancer
-
2:02
dr. konecny on resistance to parp inhibitors in ovarian cancer